• Something wrong with this record ?

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials

L. Peyrin-Biroulet, P. Arkkila, A. Armuzzi, S. Danese, M. Ferrante, . Jordi Guardiola, J. Jahnsen, E. Louis, M. Lukáš, W. Reinisch, X. Roblin, PJ. Smith, T. Kwon, J. Kim, S. Yoon, DH. Kim, R. Atreya

. 2024 ; 24 (1) : 121. [pub] 20240327

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24006646

BACKGROUND: While indirect comparison of infliximab (IFX) and vedolizumab (VDZ) in adults with Crohn's disease (CD) or ulcerative colitis (UC) shows that IFX has better effectiveness during induction, and comparable efficacy during maintenance treatment, comparative data specific to subcutaneous (SC) IFX (i.e., CT-P13 SC) versus VDZ are limited. AIM: Pooled analysis of randomised studies to compare efficacy and safety with IFX SC and VDZ in moderate-to-severe inflammatory bowel disease. METHODS: Parallel-group, randomised studies evaluating IFX SC and VDZ in patients with moderate-to-severe CD or UC were identified. Eligible studies reported ≥ 1 prespecified outcome of interest at Week 6 (reflecting treatment during the induction phase) and/or at 1 year (Weeks 50-54; reflecting treatment during the maintenance phase). Prespecified efficacy and safety outcomes considered in this pooled analysis included the proportions of patients achieving disease-specific clinical responses, clinical remission, or discontinuing due to lack of efficacy, and the proportions of patients experiencing adverse events (AEs), serious AEs, infections, serious infections, or discontinuing due to AEs. Data from multiple studies or study arms were extracted and pooled using a random-effect model; comparative analyses were performed separately for patients with CD and UC. RESULTS: We identified three eligible CD trials and four eligible UC trials that assigned over 1200 participants per disease cohort to either IFX SC or VDZ. In patients with CD, intravenous induction therapy with IFX demonstrated better efficacy (non-overlapping 95% confidence intervals [CIs]) compared with VDZ; during the maintenance phase, IFX SC showed numerically better efficacy (overlapping 95% CIs) than VDZ. A lower proportion of IFX SC-treated patients discontinued therapy due to lack of efficacy over 1 year. In patients with UC, efficacy profiles were similar with IFX SC and VDZ during the induction and maintenance phases, and a lower proportion of IFX SC-treated patients discontinued therapy due to lack of efficacy over 1 year. In both cohorts, safety profiles for IFX SC and VDZ were generally comparable during 1 year. CONCLUSION: IFX SC demonstrated better efficacy than VDZ in patients with CD, and similar efficacy to VDZ in patients with UC; 1-year safety was comparable with IFX SC and VDZ.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006646
003      
CZ-PrNML
005      
20240423155426.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12876-024-03163-5 $2 doi
035    __
$a (PubMed)38539103
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Peyrin-Biroulet, Laurent $u Department of Gastroenterology, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France
245    10
$a Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials / $c L. Peyrin-Biroulet, P. Arkkila, A. Armuzzi, S. Danese, M. Ferrante, . Jordi Guardiola, J. Jahnsen, E. Louis, M. Lukáš, W. Reinisch, X. Roblin, PJ. Smith, T. Kwon, J. Kim, S. Yoon, DH. Kim, R. Atreya
520    9_
$a BACKGROUND: While indirect comparison of infliximab (IFX) and vedolizumab (VDZ) in adults with Crohn's disease (CD) or ulcerative colitis (UC) shows that IFX has better effectiveness during induction, and comparable efficacy during maintenance treatment, comparative data specific to subcutaneous (SC) IFX (i.e., CT-P13 SC) versus VDZ are limited. AIM: Pooled analysis of randomised studies to compare efficacy and safety with IFX SC and VDZ in moderate-to-severe inflammatory bowel disease. METHODS: Parallel-group, randomised studies evaluating IFX SC and VDZ in patients with moderate-to-severe CD or UC were identified. Eligible studies reported ≥ 1 prespecified outcome of interest at Week 6 (reflecting treatment during the induction phase) and/or at 1 year (Weeks 50-54; reflecting treatment during the maintenance phase). Prespecified efficacy and safety outcomes considered in this pooled analysis included the proportions of patients achieving disease-specific clinical responses, clinical remission, or discontinuing due to lack of efficacy, and the proportions of patients experiencing adverse events (AEs), serious AEs, infections, serious infections, or discontinuing due to AEs. Data from multiple studies or study arms were extracted and pooled using a random-effect model; comparative analyses were performed separately for patients with CD and UC. RESULTS: We identified three eligible CD trials and four eligible UC trials that assigned over 1200 participants per disease cohort to either IFX SC or VDZ. In patients with CD, intravenous induction therapy with IFX demonstrated better efficacy (non-overlapping 95% confidence intervals [CIs]) compared with VDZ; during the maintenance phase, IFX SC showed numerically better efficacy (overlapping 95% CIs) than VDZ. A lower proportion of IFX SC-treated patients discontinued therapy due to lack of efficacy over 1 year. In patients with UC, efficacy profiles were similar with IFX SC and VDZ during the induction and maintenance phases, and a lower proportion of IFX SC-treated patients discontinued therapy due to lack of efficacy over 1 year. In both cohorts, safety profiles for IFX SC and VDZ were generally comparable during 1 year. CONCLUSION: IFX SC demonstrated better efficacy than VDZ in patients with CD, and similar efficacy to VDZ in patients with UC; 1-year safety was comparable with IFX SC and VDZ.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a ulcerózní kolitida $x farmakoterapie $7 D003093
650    _2
$a infliximab $x škodlivé účinky $7 D000069285
650    12
$a Crohnova nemoc $x farmakoterapie $7 D003424
650    _2
$a gastrointestinální látky $x škodlivé účinky $7 D005765
650    _2
$a indukce remise $7 D012074
650    _2
$a výsledek terapie $7 D016896
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    12
$a humanizované monoklonální protilátky $7 D061067
655    _2
$a časopisecké články $7 D016428
700    1_
$a Arkkila, Perttu $u Department of Gastroenterology, Helsinki University Hospital, Helsinki, Finland
700    1_
$a Armuzzi, Alessandro $u IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy
700    1_
$a Danese, Silvio $u Gastroenterology and Endoscopy, University Vita-Salute San Raffaele, Milan, Italy
700    1_
$a Ferrante, Marc $u Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
700    1_
$a Jordi Guardiola, $u Department of Digestive Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
700    1_
$a Jahnsen, Jørgen $u Institute of Clinical Medicine, University of Oslo, Oslo, Norway
700    1_
$a Louis, Edouard $u Department of Gastroenterology, University Hospital CHU of Liège, Liège, Belgium
700    1_
$a Lukáš, Milan $u Clinical and Research Center for Inflammatory Bowel Diseases, ISCARE Clinical Centre, Prague, Czech Republic
700    1_
$a Reinisch, Walter $u Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
700    1_
$a Roblin, Xavier $u Department of Gastroenterology and Hepatology, University Hospital of Saint-Etienne, Saint-Etienne, France
700    1_
$a Smith, Philip J $u Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
700    1_
$a Kwon, Taek $u Celltrion, Incheon, Republic of Korea
700    1_
$a Kim, Jeeyoung $u Celltrion, Incheon, Republic of Korea
700    1_
$a Yoon, Sangwook $u Celltrion, Incheon, Republic of Korea
700    1_
$a Kim, Dong-Hyeon $u Celltrion, Incheon, Republic of Korea
700    1_
$a Atreya, Raja $u Medical Department 1, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany. raja.atreya@uk-erlangen.de
773    0_
$w MED00006914 $t BMC gastroenterology $x 1471-230X $g Roč. 24, č. 1 (2024), s. 121
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38539103 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155423 $b ABA008
999    __
$a ok $b bmc $g 2080954 $s 1216413
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 24 $c 1 $d 121 $e 20240327 $i 1471-230X $m BMC gastroenterology $n BMC Gastroenterol $x MED00006914
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options